Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures

Martina Zafferani, Christina Haddad, Le Luo, Jesse Davila-Calderon, Liang Yuan Chiu, Christian Shema Mugisha, Adeline G. Monaghan, Andrew A. Kennedy, Joseph D. Yesselman, Robert J. Gifford, Andrew W. Tai, Sebla B. Kutluay, Mei Ling Li, Gary Brewer, Blanton S. Tolbert, Amanda E. Hargrove

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The SARS-CoV-2 pandemic, and the likelihood of future coronavirus pandemics, emphasized the urgent need for development of novel antivirals. Small-molecule chemical probes offer both to reveal aspects of virus replication and to serve as leads for antiviral therapeutic development. Here, we report on the identification of amiloride-based small molecules that potently inhibit OC43 and SARS-CoV-2 replication through targeting of conserved structured elements within the viral 5′-end. Nuclear magnetic resonance–based structural studies revealed specific amiloride interactions with stem loops containing bulge like structures and were predicted to be strongly bound by the lead amilorides in retrospective docking studies. Amilorides represent the first antiviral small molecules that target RNA structures within the 5′ untranslated regions and proximal region of the CoV genomes. These molecules will serve as chemical probes to further understand CoV RNA biology and can pave the way for the development of specific CoV RNA–targeted antivirals.

Original languageEnglish
Article numbereabl6096
JournalScience Advances
Volume7
Issue number48
DOIs
StatePublished - Nov 2021

Fingerprint

Dive into the research topics of 'Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures'. Together they form a unique fingerprint.

Cite this